Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 October 2018 | Story UFS | Photo UFS
Prof Ashok Chapagain, recently appointed as Senior
Prof Ashok Chapagain, recently appointed as Senior Professor in the Department of Agricultural Economics in the Faculty of Natural and Agricultural Sciences at the University of the Free State, is looking forward to working with key water-related sectors.

Prof Ashok Chapagain has recently been appointed as Senior Professor in the Department of Agricultural Economics in the Faculty of Natural and Agricultural Sciences at the University of the Free State (UFS). 

Water hub key in collaborations with research institutes

According to Prof Chapagain, the position provides a unique opportunity to help establish the university at the forefront of water research in South Africa. He is looking forward to cross-departmental collaborations on innovative research projects working with key water-related sectors, such as agriculture, business, mining etc., and establishing a water hub that would be key in external collaborations with other research institutes in South Africa and beyond.

Prior to his formal appointment at the UFS, Prof Chapagain has been remotely involved with the Department of Agricultural Economics since 2017 through his support to a number of research projects funded by the Water Research Commission (WRC). 

He is experienced in managing and coordinating international and interdisciplinary projects, ensuring technical quality and project delivery. He has vast cultural and geographical work experience, and specific water-related experience in the fields of integrated water resource management, water footprint assessment, industrial and agricultural efficiency and sustainability, irrigation, hydrology and watershed modelling, flood-risk management, river-basin planning and management, and environmental impact assessment. He has recently left the Water Footprint Network (The Netherlands), where he worked in the capacity of Science Director. Prior to joining the WFN, Prof Chapagain worked as Senior Water Adviser at WWF-UK for about six years.

Systems approach to address water issues

Prof Chapagain holds a PhD in the field of Water Resources Management and Policy Analysis from Delft University of Technology (The Netherlands), an MSc degree in Water and Environmental Resources Management from UNESCO- IHE Institute for Water Education (The Netherlands), and a Bachelor’s in Civil Engineering from IIT Roorkee (India). His professional career of 28 years can be broadly grouped under two inter-related blocks: development projects for 10 years (as an irrigation engineer in Nepal); research and application for 18 years (academia for eight years and applied work for 10 years in the Netherlands and UK). During his MSc and PhD research, he specialised in water resources and environmental management, integrated river-basin management, policy analysis, and systems analysis.

He regularly reviews articles for several scientific journals. Currently he serves as the Editor-in-Chief for the recently launched open access scientific journal H2Open, published by IWA Publishing. In addition, he serves as editor for five scientific journals, and frequently guest edits specific issues for peer-reviewed scientific journals. He has published four books, and 64 other articles and reports (25 scientific journal articles, 40 papers in conference proceedings, book chapters, and technical reports). His publications are widely cited, with 10 436 citations, and has an h-index of 34 and i10-index of 44. He applies a system approach in addressing issues on water, energy, and food securities, where managing local resources also includes global dimensions where key stakeholders are often cross-sectoral and situated outside the boxes. He has been involved in many national and international projects as a team leader, project leader, and international expert in several Asian, European, and South American countries.

For more information about Prof Chapagain and his role in the Department of Agricultural Economics, please contact Prof Chapagain at ChapagainAK@ufs.ac.za, or Dr Frikkie Maré at MareFA@ufs.ac.za or +27 51 401 2824 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept